Bank of New York Mellon Corp Sells 36,321 Shares of Charles River Laboratories International, Inc. $CRL

Bank of New York Mellon Corp lowered its holdings in Charles River Laboratories International, Inc. (NYSE:CRL) by 10.9% during the 1st quarter, Holdings Channel reports. The firm owned 295,913 shares of the medical research company’s stock after selling 36,321 shares during the period. Bank of New York Mellon Corp’s holdings in Charles River Laboratories International were worth $51,045,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also recently made changes to their positions in the business. Tema Etfs LLC purchased a new position in shares of Charles River Laboratories International in the 4th quarter worth about $26,000. Los Angeles Capital Management LLC purchased a new stake in Charles River Laboratories International during the fourth quarter worth about $42,000. Sfam LLC purchased a new stake in Charles River Laboratories International during the fourth quarter worth about $43,000. Activest Wealth Management raised its position in Charles River Laboratories International by 10,900.0% in the fourth quarter. Activest Wealth Management now owns 220 shares of the medical research company’s stock worth $44,000 after acquiring an additional 218 shares during the period. Finally, Elyxium Wealth LLC purchased a new position in Charles River Laboratories International in the fourth quarter valued at about $46,000. 98.91% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Charles River Laboratories International

In related news, Director James C. Foster sold 75,000 shares of the business’s stock in a transaction on Monday, June 29th. The stock was sold at an average price of $225.00, for a total transaction of $16,875,000.00. Following the sale, the director directly owned 31,596 shares in the company, valued at approximately $7,109,100. The trade was a 70.36% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 1.30% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on CRL shares. JPMorgan Chase & Co. decreased their price target on shares of Charles River Laboratories International from $165.00 to $160.00 and set a “neutral” rating for the company in a research note on Monday, April 13th. Sanford C. Bernstein set a $250.00 price objective on Charles River Laboratories International in a report on Wednesday, July 1st. BNP Paribas Exane set a $250.00 target price on Charles River Laboratories International in a research report on Wednesday, July 1st. Evercore restated an “outperform” rating and issued a $220.00 target price on shares of Charles River Laboratories International in a research note on Friday, May 8th. Finally, CLSA cut Charles River Laboratories International from an “outperform” rating to a “hold” rating and set a $219.00 price target on the stock. in a research report on Monday. Eleven research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $220.75.

Charles River Laboratories International Stock Up 4.7%

CRL opened at $228.99 on Friday. The company has a 50 day moving average of $197.28 and a 200 day moving average of $187.23. The company has a market cap of $11.03 billion, a PE ratio of -60.90, a price-to-earnings-growth ratio of 2.43 and a beta of 1.40. Charles River Laboratories International, Inc. has a 12 month low of $144.26 and a 12 month high of $238.85. The company has a current ratio of 1.36, a quick ratio of 1.03 and a debt-to-equity ratio of 0.90.

Charles River Laboratories International (NYSE:CRL) last issued its earnings results on Thursday, May 7th. The medical research company reported $2.06 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.96 by $0.10. The business had revenue of $995.83 million for the quarter, compared to analysts’ expectations of $977.46 million. Charles River Laboratories International had a negative net margin of 4.59% and a positive return on equity of 15.36%. The business’s revenue for the quarter was up 1.2% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $2.34 EPS. Charles River Laboratories International has set its FY 2026 guidance at 10.800-11.300 EPS. On average, sell-side analysts expect that Charles River Laboratories International, Inc. will post 11.05 EPS for the current year.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.